Drug Profile
Exenatide sustained release - Biodexa Pharmaceuticals
Alternative Names: Q-ExenatideLatest Information Update: 16 May 2023
Price :
$50
*
At a glance
- Originator Midatech
- Developer Biodexa Pharmaceuticals
- Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Type-2-diabetes-mellitus in United Kingdom (Parenteral)
- 13 Jul 2016 Early research in Type-2 diabetes mellitus in United Kingdom (Parenteral)